Similar articles

• Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial.

  Belani CP, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Fossella F; TAX 326 study group. Belani CP, et al. Lung Cancer. 2006 Aug;53(2):231-9. doi: 10.1016/j.lungcan.2006.05.003. Epub 2006 Jun 19. Lung Cancer. 2006. PMID: 16787687 Clinical Trial.
• Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).

  Belani CP, Fossella F. Belani CP, et al. Cancer. 2005 Dec 15;104(12):2766-74. doi: 10.1002/cncr.21495. Cancer. 2005. PMID: 16288485 Clinical Trial.
• Docetaxel/platinum combination provides quality-of-life advantage over vinorelbine/cisplatin in advanced lung cancer.

  [No authors listed] [No authors listed] Oncology (Williston Park). 2002 Aug;16(8):1052. Oncology (Williston Park). 2002. PMID: 12201644 No abstract available.
• Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non--small cell lung cancer: interim analysis.

  Belani C; TAX 326 Study Group. Belani C, et al. Semin Oncol. 2001 Jun;28(3 Suppl 9):10-4. Semin Oncol. 2001. PMID: 11441409 Review.
• [Vinorelbine for non-small cell lung cancer].

  Seto T. Seto T. Nihon Rinsho. 2002 May;60 Suppl 5:353-8. Nihon Rinsho. 2002. PMID: 12101688 Review. Japanese. No abstract available.